Erbitux (Cetuximab) is indicated for the treatment ofpatients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer andwithout KRAS mutations (wild type). Cetuximab is a chimericmonoclonal IgG1 antibody directed against the EGFR. Itblocks binding of endogenous EGFR ligands resulting in inhibitionof the function of the receptor and induces the internalizationof EGFR, which can lead to down-regulation of EGFR.Erbitux may be administered via a gravity drip, an infusionpump or a syringe pump. The first administration should beadministered in 120 minutes and subsequent over 60 minutes.Precautions:It is stored at a temperature between 2°Cand 8°C. Prior to the first infusion, patients must receive premedication(antihistamine and a corticosteroid) at least 1 hourbefore administration of cetuximab. Due to physico-chemicalincompatibility, must not be mixed with other medicines. Atthe Hospital ARNAS “Civico-Di Cristina-Benfratelli” ofPalermo were dispensed in the year 2013 130182 mg, in the2014 147125 mg, in the 2015 117060 mg and in the 2016(until November) 71964 mg. The highest consumption hashad in the year 2014. Following the discovery of RAS subgroups,it is seen that Erbitux works best on K-RAS subgroup,then, over the years, the SOC has varied according to thestate determination mutated or non-mutated K-RAS gene. From2015, with the marketing of Panitumumab for under K-RASGroup and the use of Bevacizumab for N-RAS, the use ofErbitux it has in fact greatly reduced.
|Numero di pagine||1|
|Rivista||JOURNAL OF BIOLOGICAL RESEARCH|
|Stato di pubblicazione||Published - 2017|